A Phase 3 interventional study of Fluticasone/ Formoterol and fluticasone/ salmeterol in Asthma, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Status unknown at 1 site in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-29.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 51st largest by planned enrollment of the 146 interventional ones that give a count, is one of 3 that started in 2017, is one of 35 in phase 3, and was the 128th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mundipharma (China) Pharmaceutical Co. Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
17 studies in Asthma by Mundipharma: none open now, none under way, none of them phase 3. Of 14 finished, 0 (0%) have results posted.
Among the 17 studies in Asthma by Mundipharma, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2017, is one of 9 in phase 3, and was the 15th registered.
Mundipharma’s Asthma studies by the year they started, since 2007.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Mundipharma’s 17 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to severe persistent, reversible asthma.
The primary objective is to show non-inferiority in the efficacy of FLUTIFORM ® pMDI (2 puffs bid) versus Seretide® pMDI (2 puffs bid) based on the change from the pre-dose forced expiratory volume in the first second (FEV1) at baseline to 2 hours post-dose FEV1 at Week 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Demonstrated a pre-dose of ≥ 40% to ≤ 80% for predicted normal values during the Screening Visit (Visit 1) following appropriate withholding of asthma medications (if applicable).
Besides The Inclusion/Exclusion Criteria Checking, Additional Randomisation Criteria Required Following Run-In Period:
Subjects with a good compliance with treatment or patient dairy. The definition of good compliance is that the completeness of diary during the last 14 days of the run-in period is at least 80%. The compliance on diary completeness will be assessed from the aspects below and agreed by the investigator and study Medical Monitor:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosage Form:2 puffs Unit Strength: Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled
Drug: Fluticasone/ Formoterol
Dosage Form:2 puffs Unit Strength: Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled
Drug: fluticasone/ salmeterol
Drug pages: Fluticasone · Formoterol
See above
Also known as: FLUTIFORM® pMDI (2 puffs bid)
Drug pages: Fluticasone · Salmeterol Xinafoate
See above
Also known as: Seretide® pMDI (2 puffs bid)
The primary efficacy endpoint is the change in pre dose Forced Expiratory Volume in one second (FEV1) from baseline to 2-hours post dose FEV1 at Week 12.
The change in pre-dose FEV1 from baseline to the 2-hours post dose FEV1 values at Week 12 will be analysed using a repeated measures ANCOVA model with fixed terms for treatment, baseline pre-dose FEV1, asthma severity, dose group, week and treatment by week interaction, and centre as a random effect. The statistical model will be used to calculate the treatment difference for the change in pre-dose FEV1 to 2 hours post-dose FEV1 at Week 12 (FLUTIFORM® - Seretide), corresponding 95% CI and p-value from the one-sided test for non-inferiority.
Time frame: 12 weeks
The key secondary efficacy endpoint is the change in pre dose FEV1 from baseline to pre dose FEV1 at Week 12.
The change in pre dose FEV1 from baseline to the pre dose FEV1 values at Week 12 will be analysed using a repeated measures ANCOVA model with fixed terms for treatment, baseline pre dose FEV1, asthma severity, dose group, week and treatment by week interaction, and centre as a random effect. The statistical model will be used to calculate the treatment difference for the change in pre-dose FEV1 from baseline at Week 12 (FLUTIFORM® - Seretide), corresponding 95% CI and p-value from the test for non-inferiority. Non-inferiority will be concluded if the lower limit of the 95% CI is greater than or equal to -200ml.
Time frame: 12 weeks
The change in pre dose FEV1 from baseline to 2-hours post dose FEV1 at Week 2 and Week 6
The change in pre-dose FEV1 from baseline to the 2-hours post dose FEV1 values at baseline (post-IMP), Week 2 and Week 6 will be analysed using a repeated measures ANCOVA model with fixed terms for treatment, baseline pre-dose FEV1, asthma severity, dose group, week and treatment by week interaction, and centre as a random effect. The statistical model will be used to calculate the treatment difference for the change in pre-dose FEV1 to 2 hours post-dose FEV1 at Week 2 and Week 6 (FLUTIFORM® - Seretide), corresponding 95% CI and p-value from the one-sided test for non-inferiority.
Time frame: 2 weeks,6 weeks
The change in pre dose FEV1 from baseline to pre dose FEV1 at Week 2 and Week 6
The change in pre dose FEV1 from baseline to the pre dose FEV1 values at Week 2 and Week 6 will be analysed using a repeated measures ANCOVA model with fixed terms for treatment, baseline pre dose FEV1, asthma severity, dose group, week and treatment by week interaction, and centre as a random effect. The statistical model will be used to calculate the treatment difference for the change in pre-dose FEV1 from baseline at Week 2 and Week 6 (FLUTIFORM® - Seretide), corresponding 95% CI and p-value from the test for non-inferiority. Non-inferiority will be concluded if the lower limit of the 95% CI is greater than or equal to -200ml.
Time frame: 2 weeks,6 weeks
The number and percentage of subjects who discontinue due to lack of efficacy will be summarised for each treatment group
The Odds Ratio for Seretide versus Flutiform, corresponding 95% CI and p-value will be presented
Time frame: up to 12 weeks
Change from baseline in daily morning and evening peak expiratory flow rate (PEFR) at Week 2, 6 and 12 and on average during the 12 week treatment period.
Morning and evening PEFR data obtained from the last 7 days prior to each visit will further be averaged for each subject to get a mean value which corresponds to the respective scheduled visit. The calculated morning and evening PEFR values at baseline, Week 2, Week 6 and Week 12 and change from baseline at each time point will be summarized by treatment group as continuous data.
Time frame: 2 weeks, 6 weeks, 12 weeks
Change from baseline in other lung function parameters (PEFR) at Week 2, Week 6 and Week 12.
The other in-clinic lung function (PEFR) values assessed at each time-point (baseline, Week 2, Week 6, Week 12 and end of study), and the change from baseline to each post-baseline time-point will be summarised by treatment group as continuous data. These lung function values will be analysed using the same methodology applied to the primary and key secondary endpoint, for change in pre- and 2 hour post-dose lung function, respectively.
Time frame: 2 weeks, 6 weeks, 12 weeks
Change from baseline in other lung function parameters (FVC) at Week 2, Week 6 and Week 12.
The other in-clinic lung function (FVC) values assessed at each time-point (baseline, Week 2, Week 6, Week 12 and end of study), and the change from baseline to each post-baseline time-point will be summarised by treatment group as continuous data. These lung function values will be analysed using the same methodology applied to the primary and key secondary endpoint, for change in pre- and 2 hour post-dose lung function, respectively.
Time frame: 2 weeks, 6 weeks, 12 weeks
Change from baseline in other lung function parameters (FEF25-75) at Week 2, Week 6 and Week 12.
The other in-clinic lung function (FEF25-75) values assessed at each time-point (baseline, Week 2, Week 6, Week 12 and end of study), and the change from baseline to each post-baseline time-point will be summarised by treatment group as continuous data. These lung function values will be analysed using the same methodology applied to the primary and key secondary endpoint, for change in pre- and 2 hour post-dose lung function, respectively.
Time frame: 2 weeks, 6 weeks, 12 weeks
Change in asthma symptom scores from baseline at Week 2, 6, and 12 and on average during the 12 week treatment period.
Asthma symptom scores obtained from the last 7 days prior to each visit will further be averaged for each subject to get a mean value which corresponds to the respective scheduled visit. The calculated asthma symptom score values at baseline, Week 2, Week 6 and Week 12 and change from baseline at each time point will be summarized by treatment group as continuous data.
Time frame: 2 weeks, 6 weeks, 12 weeks
Change in sleep disturbance scores from baseline at Week 2, 6, and 12 and on average during the 12 week treatment period
Sleep disturbance scores obtained from the last 7 days prior to each visit will further be averaged for each subject to get a mean value which corresponds to the respective scheduled visit. The calculated sleep disturbance score values at baseline, Week 2, Week 6 and Week 12 and change from baseline at each time point will be summarized by treatment group as continuous data.
Time frame: 2 weeks, 6 weeks, 12 weeks
Change in percentage of asthma control days from baseline at Week 2, 6, and 12 and on average during the 12 week treatment period.
Asthma control days will be defined as an asthma symptom score of 0 (no symptoms), a sleep disturbance score of 0 (slept through the night) and no inhalations of rescue medication. Asthma control scores obtained from the last 7 days prior to each visit will further be averaged for each subject to get a mean value which corresponds to the respective scheduled visit. The calculated percentage of asthma control days at baseline, Week 2, Week 6 and Week 12 and change from baseline at each time point will be summarized by treatment group as continuous data.
Time frame: 2 weeks, 6 weeks, 12 weeks
Proportion of patients achieving well controlled asthma [ ACQ(Asthma Control Questionnaire) score ≤ 0.75 units] at Week 12.
The number and percentage of subjects achieving well controlled asthma (ACQ score ≤ 0.75 units) at Week 12 will be summarised by treatment group. The data will be analysed using logistic regression with fixed terms for treatment, baseline ACQ score, asthma severity, dose group and centre as a random effect. The Odds Ratio for Seretide versus Flutiform, corresponding 95% CI and p-value will be presented. Subjects with missing data at Week 12 will be considered as subjects not achieving well controlled asthma for the purpose of analysis.
Time frame: 12 weeks
Change in asthma control questionnaire (ACQ) score from baseline to Week 2 and Week 12.
The ACQ questionnaire at each time-point (baseline, Week 2, Week 12 and end of study) and the change from baseline to each post-baseline time-point will be summarised by treatment group as continuous data.
Time frame: 2 weeks,12 weeks
Proportion of subjects achieving a decrease from baseline to Week 12 in ACQ(Asthma Control Questionnaire) score ≥ 0.5 units.
The number and percentage of subjects achieving a decrease from baseline to week 12 of ≥ 0.5 ACQ units will be summarised by treatment group. The data will be analysed using logistic regression with fixed terms for treatment, baseline ACQ score, asthma severity, dose group and centre as a random effect. The Odds Ratio for Seretide versus Flutiform, corresponding 95% CI and p-value will be presented. Subjects with missing data at Week 12 will be considered as subjects without a decrease of ≥ 0.5 ACQ units for the purpose of analysis.
Time frame: 12 weeks
Change in average number of occasions of daily rescue medication (salbutamol) use from baseline during the 12 week treatment period.(salbutamol) will as assessed based on subject diaries records
The mean number of occasions per day will be calculated from the subject diaries for the 12 week treatment and baseline period. For the baseline value, data from the last 7 days prior to first IMP intake will be used. The mean number of occasions per day during baseline and the 12 week treatment period and the change from baseline during the treatment period will be summarized treatment group as continuous data.
Time frame: 12 weeks
Asthma exacerbations (incidence of subjects with at least one treatment emergent asthma exacerbation and time to first treatment emergent asthma exacerbation).
Asthma exacerbations will be analyzed using two different data sources: 1. Based on exacerbations documented in the CRF by the investigator 2. Programmatically derived from the diary data and relevant CRF pages Analyses on exacerbations documented by the investigator on the CRF will be considered the main analyses. Analyses on exacerbations obtained programmatically from the diary data will be considered as supportive analyses.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2017 (actual). Primary completion is estimated for Dec 2019, 30 months after the start.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 30 months is above that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Formoterol
Mundipharma (China) Pharmaceutical Co. Ltd →